Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health and Novaliq announced that their investigational treatment NOV03 successfully met primary endpoints in two pivotal Phase 3 trials for treating dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The latest trial results demonstrated significant improvements in total corneal fluorescein staining and eye dryness scores at day 57. With potential FDA submission in Q2 2022, NOV03 could become the first pharmaceutical therapy available in the U.S. targeting this common ocular condition affecting approximately 18 million Americans.
Bausch Health Companies (NYSE/TSX: BHC) will announce its first-quarter financial results on May 10, 2022. A conference call and live webcast will be held at 8:00 a.m. ET to discuss these results and provide a business update. Investors can access materials through the Investor Relations section of the Bausch Health website before the call.
Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies (NYSE/TSX: BHC), has announced its initial public offering (IPO), offering 35 million common shares with an expected price range of $21 to $24 per share. A 30-day option for underwriters to purchase an additional 5.25 million shares is also planned. Post-IPO, Bausch Health will hold approximately 90% of Bausch + Lomb's shares. The IPO aims for listing on the NYSE and TSX under the ticker symbol 'BLCO'. Bausch + Lomb will not receive any IPO proceeds.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced an arrangement agreement to facilitate the separation of its eye health business, Bausch + Lomb Corporation. This agreement outlines terms for transferring shares of Bausch + Lomb to Bausch Health shareholders post-IPO. The arrangement is subject to various conditions, including regulatory approvals and tax opinions to ensure a tax-free transaction. A special shareholder meeting will be convened after the IPO for further consideration. Completion of the process is contingent upon meeting all aforementioned conditions.
Bausch + Lomb, a leading eye health business of Bausch Health Companies (NYSE/TSX: BHC), will showcase 13 scientific poster presentations at the ARVO annual meeting from May 1-4, 2022. Presentations will include pivotal Phase 3 trial results for NOV03, an investigational treatment for dry eye disease, and data on XIPERE® for macular edema associated with uveitis. The company emphasizes its commitment to research and innovation in ophthalmology, aiming to provide valuable insights for eye care professionals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced four poster presentations at the Florida Society of Dermatology Physician Assistants (FSDPA) New Wave Dermatology Conference from April 28 to May 1, 2022. The presentations will include new clinical data on ARAZLO® (tazarotene) lotion for truncal acne, marking its first open-label clinical study for this condition. Additional data on DUOBRII®, JUBLIA®, and SILIQ® will also be shared, highlighting the company's commitment to advancing dermatological treatments.
Bausch Health (BHC) and Novaliq GmbH announced positive results from the pivotal Phase 3 trial (GOBI) for NOV03, a novel eye drop treatment for dry eye disease associated with Meibomian gland dysfunction. The study involved 597 participants and demonstrated that NOV03 met both primary endpoints: a significant decrease in total corneal fluorescein staining and improved eye dryness scores at day 57 (P<0.001). The treatment was well tolerated with low adverse event rates. The companies plan to submit for FDA approval in Q2 2022, potentially addressing a significant unmet medical need.
Bausch + Lomb has achieved a significant milestone by recycling over 48 million units, equivalent to 290,145 pounds of contact lenses and related materials, through its ONE by ONE and Biotrue® Eye Care Recycling programs. These initiatives, launched in collaboration with TerraCycle, prevent waste from ending up in landfills. The ONE by ONE program has recycled over 48 million items since 2016, while the Biotrue® program has collected over 153,222 items since its launch in April 2021. Both programs highlight Bausch + Lomb's commitment to sustainability in eye health.
Bausch Health Companies Inc. (BHC) announced a planned separation of its eye health business, Bausch + Lomb, which intends to enter a new credit agreement. This agreement includes a $2.5 billion term loan and a $500 million revolving credit facility, both maturing in 2027. The funds from the term loan will be used to repay an intercompany note to Bausch Health following Bausch + Lomb's initial public offering. The completion of these transactions is subject to market conditions and other approvals, anticipated to close in Q2 2022.
Bausch Health (NYSE/TSX: BHC) announced the presentation of 10 podium and 2 poster presentations at the upcoming American Society of Cataract and Refractive Surgery annual meeting, from April 22-26, 2022, in Washington, D.C. Key highlights include results from the pivotal Phase 3 trial of NOV03, aimed at treating dry eye disease associated with Meibomian gland dysfunction. The trial results will be featured in a presentation titled "Efficacy of Perfluorohexyloctane on Signs and Symptoms of Dry Eye Disease: The Gobi Study." Bausch + Lomb aims to support surgeons with ongoing scientific exchange.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
